Sprouty3 and Sprouty4, Two Members of a Family Known to Inhibit FGF-Mediated Signaling, Exert Opposing Roles on Proliferation and Migration of Glioblastoma-Derived Cells

Abstract

Dysregulation of receptor tyrosine kinase-induced pathways is a critical step driving the oncogenic potential of brain cancer. In this study, we investigated the role of two members of the Sprouty (Spry) family in brain cancer-derived cell lines. Using immunoblot analyses we found essential differences in the pattern of endogenous Spry3 and Spry4 expression. While Spry4 expression was mitogen-dependent and repressed in a number of cells from higher malignant brain cancers, Spry3 levels neither fluctuated in response to serum withdrawal nor were repressed in glioblastoma (GBM)-derived cell lines. In accordance to the well-known inhibitory role of Spry proteins in fibroblast growth factor (FGF)-mediated signaling, both Spry proteins were able to interfere with FGF-induced activation of the MAPK pathway although to a different extent. In response to serum solely, Spry4 exerts its role as a negative regulator of MAPK activation. Ectopic expression of Spry4 inhibited proliferation and migration of GBM-originated cells, positioning it as a tumor suppressor in brain cancer. In contrast, elevated Spry3 levels accelerated both proliferation and migration of these cell lines, while repression of Spry3 levels using shRNA caused a significant diminished growth and migration velocity rate of a GBM-derived cell line. This argues for a tumor-promoting function of Spry3 in GBMs. Based on these data we conclude that Spry3 and Spry4 fulfill different if not opposing roles within the cancerogenesis of brain malignancies.

The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives

“…Activated FGFRs localize to the cytoplasm, where they undergo lysosomal degradation or the recycling process, which are partially controlled by CbL-mediated monoubiquitylation or the LIS1/NDE1 complex [ 25 , 32 ]. FGFR signaling may be negatively regulated by MAPK phosphatase 3, Sprouty proteins, and SeF (similar expression to FGF, also known as IL17RD) family members [ 33 , 34 , 35 ] ( Figure 1 ). As the down-regulation of the activated receptors is an important process in order to prevent altered signaling, a defective FGFR ubiquitination system and/or an error in the mitigation pathway could induce aberrant cell growth and malignant transformation [ 36 ].…”

Therapeutic Target Discovery Using High-Throughput Genetic Screens in Acute Myeloid Leukemia

“…SPRY3, an antagonist of the fibroblast growth factor (FGF) pathway [ 120 ], was identified as a therapeutic modulator in a genome-wide CRISPR library screen (64,751 sgRNAs targeting 18,080 genes) performed in an FLT3-mutant AML cell line (MV4-11) treated with a second-generation FLT-3 inhibitor AC220 [ 32 ]. The authors discovered that knockdown of SPRY3 triggers resistance to AC220 by reactivation of the FGF/Ras/ERK signaling pathway.…”

SPRY4 regulates trophoblast proliferation and apoptosis via regulating IFN‐γ‐induced STAT1 expression and activation in recurrent miscarriage

“…8 SPRY4 is ubiquitously expressed in human tissues 11 and is initially known as a tumour suppressor involved in several cancers. SPRY4 is decreased in prostate cancer, 12 non-small-cell lung cancer, 13,14 breast cancer, 15 melanoma, 16 and brain cancer, 17 and overexpression of SPRY4 inhibits cell proliferation, migration, and invasion in these cancers. However, a recent study showed that SPRY4 plays a tumorigenic role in testicular germ cell tumours.…”